Arri Vent Biopharma, Inc. AVBP
We take great care to ensure that the data presented and summarized in this overview for ArriVent Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AVBP
Top Purchases
Top Sells
About AVBP
Insider Transactions at AVBP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2024
|
Hillhouse Investment Management, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
555,555
+11.02%
|
$9,999,990
$18.0 P/Share
|
|
Jan 30
2024
|
Hillhouse Investment Management, Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,929,117
+28.69%
|
-
|
|
Jan 30
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+20.76%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
James Healy Director |
BUY
Conversion of derivative security
|
Indirect |
1,252,308
+50.0%
|
-
|
|
Jan 30
2024
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+12.8%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
2,582,884
+38.33%
|
-
|
|
Jan 30
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+12.8%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,582,884
+38.33%
|
-
|
Last 12 Months Summary
Buy / Acquisition
12.2M
Shares
From
8
Insiders
| Conversion of derivative security | 10.3M shares |
|---|---|
| Open market or private purchase | 1.89M shares |
Sell / Disposition
0
Shares
From
0
Insiders